Retraction of Publication Rev Neurol (Paris). 2020 Sep 15;S0035-3787(20)30660-3. doi: 10.1016/j.neurol.2020.08.001. Online ahead of print.

WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies DOI: 10.1016/j.neurol.2020.08.001

The most damming report of anti-CD20 risk of MS has been withdrawn by the authors and editors. Is this view all made up?

They estimated that of 25,436 treated MS patients (7621 males; 30%, 17,815 females; 70%) were identified, with 144 of whom (0.57%) reported as confirmed cases of COVID-19 (45 males; 31.2%, 99 females; 68.8%). A total of 28 deaths (9 males; 32.1%, 19 females; 67.9%), among fingolimod- (one female), dimethyl fumarate- (one female), and rituximab-treated (8 males; 30.8%, 18 females; 69.2%) groups were identified. 21 (80.7%) out of 26 deceased rituximab-treated patients had progressive forms of MS, and 5 (19.2%) patients had other comorbidities. The relative risk was highest in rituximab-treated patients (5.56; 95% CI: 2.45–12.65), followed by natalizumab-treated patients (1.88; 95% CI: 0.42–8.39) and fingolimod-treated patients (1.87; 95% CI: 0.61–5.70).

This says CD20 depleting increases risk of COVID-19 6 times. However why is it withdrawn? Is it all made up?

About the author



  • This is the Elsevier text on withdrawn articles:

    Only used for Articles in Press which represent early versions of articles and sometimes contain errors, or may have been accidentally submitted twice. Occasionally, but less frequently, the articles may represent infringements of professional ethical codes, such as multiple submission, bogus claims of authorship, plagiarism, fraudulent use of data or the like. Articles in Press (articles that have been accepted for publication but which have not been formally published and will not yet have the complete volume/issue/page information) that include errors, or are discovered to be accidental duplicates of other published article(s), or are determined to violate our journal publishing ethics guidelines in the view of the editors (such as multiple submission, bogus claims of authorship, plagiarism, fraudulent use of data or the like), may be “Withdrawn” from ScienceDirect. Withdrawn means that the article content (HTML and PDF) is removed and replaced with a HTML page and PDF simply stating that the article has been withdrawn according to the Elsevier Policy on Article in Press Withdrawal with a link to the current policy document.

    It could have been any number of reasons, including plagiarism, bogus claims of authorship, or submission of same article to multiple journals. We’ll probably never know. The principal author, M. Etemadifar, has a fairly long publication history on MS in Iran.

  • Well it doesn’t fit or promote the narrative does it? –

    … hit it fast and hard (even though we only find out the long term effects later) viruses and bacterial infections can be monitored and managed; and your quality of life won’t be compromised…

    Pharma and researchers don’t won’t the truth really do they let’s face it

    In 70 years no one has found a cure or anything like it and the research is focused on repackaging and repurposing dirty old toxic drugs

    That’s a lorra time and a lorra money made up

    Suggesting an alarming report is made up, says it all…

By MouseDoctor



Recent Posts

Recent Comments